See more : China Weaving Materials Holdings Limited (3778.HK) Income Statement Analysis – Financial Results
Complete financial analysis of NEXGEL, Inc. (NXGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NEXGEL, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Wilmington plc (WIL.L) Income Statement Analysis – Financial Results
- AVI Limited (AVSFY) Income Statement Analysis – Financial Results
- Tokyo Rope Mfg. Co., Ltd. (5981.T) Income Statement Analysis – Financial Results
- FedEx Corporation (FDX.SW) Income Statement Analysis – Financial Results
- PT Bank Bumi Arta Tbk (BNBA.JK) Income Statement Analysis – Financial Results
NEXGEL, Inc. (NXGL)
About NEXGEL, Inc.
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.09M | 2.05M | 1.55M | 674.00K | 717.00K | 2.21M | 1.99M | 2.15M |
| Cost of Revenue | 3.47M | 1.79M | 1.54M | 965.00K | 854.00K | 1.70M | 1.85M | 2.27M |
| Gross Profit | 619.00K | 256.00K | 9.00K | -291.00K | -137.00K | 514.00K | 147.00K | -114.00K |
| Gross Profit Ratio | 15.14% | 12.50% | 0.58% | -43.18% | -19.11% | 23.23% | 7.38% | -5.30% |
| Research & Development | 103.00K | 367.00K | 31.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.02M | 2.38M | 2.54M | 1.96M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 620.00K | 436.00K | 320.00K | 13.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.99M | 3.24M | 2.54M | 1.97M | 1.79M | 2.40M | 1.12M | 1.75M |
| Other Expenses | 0.00 | 3.00K | 13.00K | 8.00K | 0.00 | 0.00 | 0.00 | 25.00K |
| Operating Expenses | 4.10M | 3.60M | 2.58M | 1.97M | 1.79M | 2.40M | 1.12M | 1.75M |
| Cost & Expenses | 7.57M | 5.40M | 4.12M | 2.93M | 2.64M | 4.10M | 2.96M | 4.02M |
| Interest Income | 0.00 | 1.34M | 2.00M | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 15.00K | 1.34M | 2.00M | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 443.00K | 301.00K | 113.00K | 50.00K | 67.00K | 322.00K | 316.00K | 324.00K |
| EBITDA | -2.73M | -3.11M | -2.20M | -2.20M | -1.86M | -1.57M | -653.00K | -1.54M |
| EBITDA Ratio | -66.76% | -148.63% | -158.41% | -326.71% | -259.00% | -70.76% | -32.78% | -71.56% |
| Operating Income | -3.48M | -3.35M | -2.57M | -2.26M | -1.92M | -1.89M | -969.00K | -1.86M |
| Operating Income Ratio | -85.03% | -163.48% | -165.70% | -335.31% | -268.34% | -85.31% | -48.64% | -86.62% |
| Total Other Income/Expenses | 289.00K | -1.40M | -1.74M | -4.00K | 1.00K | 0.00 | 0.00 | 25.00K |
| Income Before Tax | -3.19M | -4.75M | -4.31M | -2.26M | -1.92M | -1.89M | -969.00K | -1.84M |
| Income Before Tax Ratio | -77.97% | -231.74% | -277.89% | -335.91% | -268.20% | -85.31% | -48.64% | -85.46% |
| Income Tax Expense | 0.00 | 1.40M | 2.00M | 18.00K | -104.86K | 160.86K | -16.00K | -63.00K |
| Net Income | -3.16M | -6.14M | -6.31M | -2.28M | -1.92M | -1.89M | -953.00K | -1.78M |
| Net Income Ratio | -77.21% | -300.00% | -406.71% | -338.58% | -268.20% | -85.31% | -47.84% | -82.53% |
| EPS | -0.56 | -1.10 | -1.13 | -0.02 | -0.14 | -0.34 | -0.17 | -0.32 |
| EPS Diluted | -0.56 | -1.10 | -1.13 | -0.02 | -0.14 | -0.34 | -0.17 | -0.32 |
| Weighted Avg Shares Out | 5.67M | 5.57M | 5.57M | 104.28M | 13.57M | 5.57M | 5.57M | 5.57M |
| Weighted Avg Shares Out (Dil) | 5.67M | 5.57M | 5.57M | 104.28M | 13.57M | 5.57M | 5.57M | 5.57M |
NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America
LANGHORNE, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the first product to...
NEXGEL Acquires International Beauty Brand, Silly George
Acquisition further expands NEXGEL Health, Wellness, and Beauty consumer product portfolio Silly George is on a revenue run rate of approximately $2 million LANGHORNE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a...
NEXGEL, Inc. (NXGL) Q1 2024 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL ) Q1 2024 Results Conference Call May 13, 2024 4:30 PM ET Company Participants Valter Pinto - Managing Director, KCSA Strategic Communications Adam Levy - Chief Executive Officer Adam Drapczuk - Chief Financial Officer Conference Call Participants...
NEXGEL, Inc. (NXGL) Q4 2023 Earnings Call Transcript
NEXGEL, Inc. (NXGL) Q4 2023 Earnings Call Transcript
NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year
LANGHORNE, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the fourth quarter and full...
NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday
LANGHORNE, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced rescheduling its financial results...
NEXGEL to Report Fourth Quarter and Full Year 2023 Financial Results on March 28th
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.
NEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th
LANGHORNE, Pa., March 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief...
NEXGEL Subsidiary, CG Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024
LANGHORNE, Pa., Jan. 09, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced a 12,000 square foot...
NEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America
LANGHORNE, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced a partnership with STADA...
Source: https://incomestatements.info
Category: Stock Reports